PLPerry L. Lim

Perry L. Lim

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Perry L. Lim has a total of 23 co-authors. Here are the top co-authors by number of shared publications:

  • Christopher M. Melnic

    Department of Orthopaedic Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; Department of Orthopaedic Surgery, Newton-Wellesley Hospital, Newton, Massachusetts

    3 shared publications
  • Hany S. Bedair

    Department of Orthopaedic Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; Department of Orthopaedic Surgery, Newton-Wellesley Hospital, Newton, Massachusetts

    3 shared publications
  • Donnell L. Williams

    Department of Orthopaedic Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; Department of Orthopaedic Surgery, Newton-Wellesley Hospital, Newton, Massachusetts

    2 shared publications
  • Nicholas Sauder

    Department of Orthopaedic Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; Department of Orthopaedic Surgery, Newton-Wellesley Hospital, Newton, Massachusetts

    2 shared publications
  • Rohan Singh

    Department of Orthopaedic Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; Department of Orthopaedic Surgery, Newton-Wellesley Hospital, Newton, Massachusetts

    2 shared publications
  • Adam J. Murrietta

    Department of Orthopaedic Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; Department of Orthopaedic Surgery, Newton-Wellesley Hospital, Newton, Massachusetts

    1 shared publication

Latest Publications

  • Does Prior Arthroscopy Delay Clinically Relevant Improvement Timelines Following Unicompartmental Knee Arthroplasty and Primary Total Knee Arthroplasty?

    by Donnell L. Williams, Nicholas Sauder, Rohan Singh, Adam J. Murrietta, Perry L. Lim, Hany S. Bedair, Christopher M. Melnic


  • Do Surgeon Volume and Experience Correlate With Patient-Reported Outcomes or Costs of Care in Unicompartmental Knee Arthroplasty?

    by Donnell L. Williams, Rohan Singh, Nicholas Sauder, Shian L. Peterson, Perry L. Lim, Christopher M. Melnic, Hany S. Bedair

  • Total joint arthroplasty patients who experience the minimal clinically important difference for worsening (MCID-W) have higher revision rates at 1, 3, and 5 years postoperatively:

    by Perry L. Lim, Nicholas Sauder, Shian L. Peterson, Christopher M. Melnic, Hany S. Bedair

    Introduction The Minimal Clinically Important Difference (MCID) is critical in assessing patient-reported outcomes following total joint arthroplasty (TJA). Although many studies consider the MCID for Improvement (MCID-I), thresholds have also been defined for the MCID for Worsening (MCID-W). However, the potential impact of the MCID-W on surgical outcomes in TJA is under-investigated. This study investigated the association between the MCID-W and revision rate. Materials and methods This retrospective study was performed using 2787 primary TJAs—1563 total knee arthroplasties (TKAs) and 1224 total hip arthroplasties (THAs)—with minimum five-year follow-up. Patient-Reported Outcomes Measurement Information System Physical Function Short Form 10a (PROMIS PF-10a) scores were collected preoperatively and at one-year postoperatively. Patients were classified based on experiencing MCID-I, MCID-W, or “no change” after TJA (scores between MCID-I and MCID-W). MCID-W and MCID-I values were determined by a distribution-based method. Revision-free survival was compared at 1 year, 3 years, and 5 years postoperatively. Results The overall revision rate for the entire TJA cohort was 1.1% at 1 year, 1.8% at 3 years, and 2.2% at 5 years postoperatively. TJA patients who experienced MCID-W had a higher revision rate than MCID-I patients at 1 year (3.6 versus 0.8%, P < 0.001), 3 years (5.3 versus 1.1%, P < 0.001), and 5 years postoperatively (5.7 versus 1.5%, P < 0.001). Similarly, stratifying into TKAs and THAs revealed an association between MCID-W and higher revision rates. Revision-free survival curves for MCID-W patients revealed lower survival at 1 year (P < 0.001), 3 years (P < 0.001), and 5 years (P < 0.001). Conclusions Patients experiencing the MCID-W are more likely to undergo revision surgery at 1, 3, and 5 years following both THA and TKA procedures. The MCID-W may be a useful tool to help identify postoperative THA and TKA patients at highest risk for revision surgery. Future studies utilizing MCID-W as a predictive tool are needed to determine its effectiveness in optimizing TJA patient outcomes.


  • Open Access

    Commentary: Recovery Time and Success: A Comparative Study of Robotic and Manual Total Hip Arthroplasty Outcomes

    by Jacob S. Borgida, Perry L. Lim, Hany S. Bedair, Christopher M. Melnic

    Total hip arthroplasty (THA) is a well-established procedure that has significantly improved the quality of life for patients suffering from end-stage hip osteoarthritis and other debilitating hip conditions. Over the past few decades, robotic-assisted THA (rTHA) utilization has grown significantly, with projections suggesting that rTHA may comprise up to two-thirds of all THA procedures by 2030


  • Open Access

    The Human Microbiome and Its Role in Musculoskeletal Disorders

    by Khaled Aboushaala, Arnold Y. L. Wong, Juan Nicolas Barajas, Perry Lim, Lena Al-Harthi, Ana Chee, Christopher B. Forsyth, Chun-Do Oh, Sheila J. Toro, Frances M. K. Williams, et al.

    Musculoskeletal diseases (MSDs) are characterized as injuries and illnesses that affect the musculoskeletal system. MSDs affect every population worldwide and are associated with substantial global burden. Variations in the makeup of the gut microbiota may be related to chronic MSDs. There is growing interest in exploring potential connections between chronic MSDs and variations in the composition of gut microbiota. The human microbiota is a complex community consisting of viruses, archaea, bacteria, and eukaryotes, both inside and outside of the human body. These microorganisms play crucial roles in influencing human physiology, impacting metabolic and immunological systems in health and disease. Different body areas host specific types of microorganisms, with facultative anaerobes dominating the gastrointestinal tract (able to thrive with or without oxygen), while strict aerobes prevail in the nasal cavity, respiratory tract, and skin surfaces (requiring oxygen for development). Together with the immune system, these bacteria have coevolved throughout time, forming complex biological relationships. Changes in the microbial ecology of the gut may have a big impact on health and can help illnesses develop. These changes are frequently impacted by lifestyle choices and underlying medical disorders. The potential for safety, expenses, and efficacy of microbiota-based medicines, even with occasional delivery, has attracted interest. They are, therefore, a desirable candidate for treating MSDs that are chronic and that may have variable progression patterns. As such, the following is a narrative review to address the role of the human microbiome as it relates to MSDs.